Epidemiology of myasthenia gravis in France: Incidence, prevalence, and comorbidities based on national healthcare insurance claims data
CONCLUSION: The incidence and prevalence rates of MG are significantly higher than those previously reported in the literature and the incidence increases with age. The excess risk of cancer raises concerns for MG patients, in particular, concerning the management of immunosuppressive drugs.PMID:38582663 | DOI:10.1016/j.neurol.2024.02.392 (Source: Revue Neurologique)
Source: Revue Neurologique - April 6, 2024 Category: Neurology Authors: S Keovilayhong A Mulliez L Feral C Chenaf P Clavelou X Moisset F Taithe L Poncet Megemont Source Type: research
Epileptic encephalopathies and progressive neurodegeneration
Rev Neurol (Paris). 2024 Apr 5:S0035-3787(24)00481-8. doi: 10.1016/j.neurol.2024.03.004. Online ahead of print.ABSTRACTDevelopmental encephalopathies (DE), epileptic encephalopathies (EE) and developmental and epileptic encephalopathies (DEE) are overlapping neurodevelopmental disorders characterized by early-onset, often severe epileptic seizures, developmental delay, or regression and have multiple etiologies. Classical nosology in child neurology distinguished progressive and nonprogressive conditions. A progressive course with global cognitive worsening in DEE is usually attributed to severe seizures and electroencepha...
Source: Revue Neurologique - April 6, 2024 Category: Neurology Authors: R Guerrini V Conti Source Type: research
Impact of multiple sclerosis on employment and income: Insights from a random sample representative of private sector employees in France using longitudinal administrative data
In conclusion, this study shows that the effects of MS on the employed population in the private sector occur early in the disease course and are cumulative, and that replacement income helps to reduce the loss of resources thanks to the French health and social system.PMID:38582662 | DOI:10.1016/j.neurol.2024.02.389 (Source: Revue Neurologique)
Source: Revue Neurologique - April 6, 2024 Category: Neurology Authors: E Leray C Regaert E Duguet S Guillaume S Pichetti M Espagnacq Source Type: research
Epidemiology of myasthenia gravis in France: Incidence, prevalence, and comorbidities based on national healthcare insurance claims data
CONCLUSION: The incidence and prevalence rates of MG are significantly higher than those previously reported in the literature and the incidence increases with age. The excess risk of cancer raises concerns for MG patients, in particular, concerning the management of immunosuppressive drugs.PMID:38582663 | DOI:10.1016/j.neurol.2024.02.392 (Source: Revue Neurologique)
Source: Revue Neurologique - April 6, 2024 Category: Neurology Authors: S Keovilayhong A Mulliez L Feral C Chenaf P Clavelou X Moisset F Taithe L Poncet Megemont Source Type: research
Epileptic encephalopathies and progressive neurodegeneration
Rev Neurol (Paris). 2024 Apr 5:S0035-3787(24)00481-8. doi: 10.1016/j.neurol.2024.03.004. Online ahead of print.ABSTRACTDevelopmental encephalopathies (DE), epileptic encephalopathies (EE) and developmental and epileptic encephalopathies (DEE) are overlapping neurodevelopmental disorders characterized by early-onset, often severe epileptic seizures, developmental delay, or regression and have multiple etiologies. Classical nosology in child neurology distinguished progressive and nonprogressive conditions. A progressive course with global cognitive worsening in DEE is usually attributed to severe seizures and electroencepha...
Source: Revue Neurologique - April 6, 2024 Category: Neurology Authors: R Guerrini V Conti Source Type: research
Impact of multiple sclerosis on employment and income: Insights from a random sample representative of private sector employees in France using longitudinal administrative data
In conclusion, this study shows that the effects of MS on the employed population in the private sector occur early in the disease course and are cumulative, and that replacement income helps to reduce the loss of resources thanks to the French health and social system.PMID:38582662 | DOI:10.1016/j.neurol.2024.02.389 (Source: Revue Neurologique)
Source: Revue Neurologique - April 6, 2024 Category: Neurology Authors: E Leray C Regaert E Duguet S Guillaume S Pichetti M Espagnacq Source Type: research
Epidemiology of myasthenia gravis in France: Incidence, prevalence, and comorbidities based on national healthcare insurance claims data
CONCLUSION: The incidence and prevalence rates of MG are significantly higher than those previously reported in the literature and the incidence increases with age. The excess risk of cancer raises concerns for MG patients, in particular, concerning the management of immunosuppressive drugs.PMID:38582663 | DOI:10.1016/j.neurol.2024.02.392 (Source: Revue Neurologique)
Source: Revue Neurologique - April 6, 2024 Category: Neurology Authors: S Keovilayhong A Mulliez L Feral C Chenaf P Clavelou X Moisset F Taithe L Poncet Megemont Source Type: research
Gene editing as a therapeutic strategy for spinocerebellar ataxia type-3
Rev Neurol (Paris). 2024 Apr 4:S0035-3787(24)00478-8. doi: 10.1016/j.neurol.2024.03.003. Online ahead of print.ABSTRACTSpinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, is a neurodegenerative disease caused by expanded polyglutamine repeats in exon 10 of the ataxin-3 gene, ATXN3. The accumulation of mutant ATXN3 protein leads to severe clinical manifestations and premature death. Clinically, SCA3 pathology is characterized by progressive ataxia leading to motor incoordination that may affect balance, gait and speech, and neuropathologically by a progressive degeneration of the spinal cord and cere...
Source: Revue Neurologique - April 5, 2024 Category: Neurology Authors: N D églon Source Type: research
Descriptive study of general practitioner's practices and knowledge about Parkinson's disease in the north of France
CONCLUSIONS: These findings could be useful to guide implementation of new measures supporting more holistic care for PD patients; PD expert centers in France could provide complementary information and training for GPs.PMID:38556412 | DOI:10.1016/j.neurol.2024.02.388 (Source: Revue Neurologique)
Source: Revue Neurologique - March 31, 2024 Category: Neurology Authors: M Aubignat H Skierkowski M Tir Source Type: research
Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapies
Rev Neurol (Paris). 2024 Mar 28:S0035-3787(24)00476-4. doi: 10.1016/j.neurol.2024.01.008. Online ahead of print.ABSTRACTNeuromyelitis optica spectrum disorder (NMOSD) is a rare but debilitating autoimmune disease of the central nervous system (CNS) for which several biotherapies have recently been approved on the market. Historically, NMOSD disease-modifying treatments relied on wide-spectrum off-label immunosuppressants, such as azathioprine, mycophenolate mofetil, and cyclophosphamide. Since 2015, evidence has accumulated to support off-label biotherapies (rituximab and tocilizumab) and to approve satralizumab, inebilizu...
Source: Revue Neurologique - March 29, 2024 Category: Neurology Authors: S Demuth N Collongues Source Type: research
